Modality
Nanobody
MOA
Cl18.2
Target
FLT3
Pathway
Epigenetic
DravetCeliac
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ May 2026
Phase 1Current
NCT03955345
1,110 pts·Dravet
2018-04→2026-05·Not yet recruiting
NCT04510079
662 pts·Celiac
2022-01→2025-06·Not yet recruiting
1,772 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-1410mo agoPh2 Data· Celiac
2026-05-071mo awayPh2 Data· Dravet
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1/2
Not yet…
P1/2
Not yet…
Catalysts
Ph2 Data
2025-06-14 · 10mo ago
Celiac
Ph2 Data
2026-05-07 · 1mo away
Dravet
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03955345 | Phase 1/2 | Dravet | Not yet recr... | 1110 | VA |
| NCT04510079 | Phase 1/2 | Celiac | Not yet recr... | 662 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Sotorapivir | Moderna | Approved | FLT3 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| Zanumavacamten | Iovance | Phase 2 | FLT3 | |
| RAR-440 | Ultragenyx | Phase 2 | FLT3 |